Fulgent Genetics
UBS Initiates Coverage of Bio-Rad Laboratories, Fulgent Genetics, Bio-Techne
The global financial services firm gave ratings of Buy, Neutral, and Buy to Bio-Rad, Fulgent, and Bio-Techne, respectively.
Fulgent Genetics Core Revenues Rise 17 Percent
Total revenues were down approximately 20 percent, which the El Monte, California-based molecular diagnostics firm attributed to a year-over-year decline in COVID-19 testing.
Fulgent Genetics Core Revenues Jump 48 Percent
The firm noted a momentum in precision diagnostics, anatomic pathology, and pharma services while declining COVID-19 revenues caused an overall revenue decline.
GenomeWeb Top 40 Falls 7 Percent in May As Broader Market Delivers Mixed Results
The Dow Jones Industrial Average was down 3 percent, while the Nasdaq was up 6 percent, and the Nasdaq Biotech Index was down nearly 3 percent.
Fulgent Genetics Raises Guidance After Strong Jump in Q1 Core Revenues
As a result of the strong core growth, the company raised its full-year revenue guidance to $250 million from previous guidance of $240 million.